This first-of-its-kind network is a group of Canadian investigators at centres of excellence coast to coast who are collaborating to share ideas, data and findings related to pancreatic cancer. Created by Pancreatic Cancer Canada in 2016, this pan-Canadian initiative aims to better understand pancreatic cancer in order to advance knowledge, diagnosis and treatments for patients.
With this group of experts, PancOne™ is able to leverage information from a comprehensive regional population to provide data and insights to national and global institutes and partners.
There has been little progress in the fight against pancreatic cancer. The hard truth of this horrible disease is that 93% of people diagnosed don’t live past 5 years. Our researchers believe this is because there are many different subtypes of pancreatic cancer, yet all are being treated with the same type of chemotherapy. Personalized medicines for each subtype may result in higher survival rates.
The goal of PancOne™ is to identify these subtypes, find the right treatment for the right patients at the right time. At the same time, they will work to discover new and innovative therapies that provide better patient care for survival and quality of life.
They will not work alone – that is the essence of this network. “Big Data” in medical research means that global leaders need to work together to share knowledge and ideas. Through the funding support of donors to Pancreatic Cancer Canada, PancOne™ will make a significant impact in learning about this disease and treating it in ways never before achieved.
Centres of Excellence:
- Princess Margaret Cancer Centre
- BC Cancer Foundation
- McGill University Health Centre Foundation
- University of Calgary
- QEII Health Sciences Centre Foundation
- Kingston Health Sciences Centre
- The Ottawa Hospital
This partnership will build on the infrastructure available in Canada including expertise in clinical trials, metastatic pancreatic cancer management, familial pancreatic cancer, cancer genomics and state of the art tumour sequencing facilities at the Ontario Institute for Cancer Research (OICR) and BC Cancer Agency Genome Science Centre (BCCA GSC), in order to define clinically relevant metastatic pancreatic cancer subtypes, understand mechanisms underlying sensitivity and resistance to chemotherapy, and facilitate precision medicine approaches.
This study will be available to patients with advanced pancreatic cancer, and will involve tumour biopsies, molecular analysis of the cancers, and ongoing close monitoring for response to therapy. In addition the molecular analysis information will be used to direct subsequent therapy tailored to specific characteristics of that specific cancer.